Prof. Jeffrey Pollard is a Director of the MRC Centre for Reproductive Health (MRC-CRH), University of Edinburgh. He has been investigating the roles of macrophages in development, tissue repair and cancer for almost 40 years. His group was the first to show that tumour-associated macrophages promote the progression of tumours to metastasis in part, through the establishment of a suppressive immune microenvironment that supports tumour cell survival. Prof. Pollard has published over 270 scientific papers and is one of the most cited researchers in science. He is a Fellow of the Royal Society of Edinburgh, Fellow of the Royal Society of Biology, Fellow of the Academy of Medical Sciences, Fellow of the American Association for the Advancement of Sciences and is a Wellcome Trust Senior Investigator. He has been awarded many honours, most notably the American Cancer Society Medal of Honor for Basic Sciences.
Dr. Cassetta is an immunologist with in-depth knowledge of human myeloid cell biology applied to different human diseases. He has extensive experience in human macrophage biology, clinical material handling, multicolour flow cytometry, and genome-wide studies that contributed to the development of the Macomics screening platform.
He is an author of multiple publications in high-impact international scientific journals including Cancer Cell, Nature Communications, Journal of Experimental Medicine, Blood, PNAS, Nature Reviews Drug Discovery. He was awarded the Innovation Prize cup 2019 as a young entrepreneur for the spinout company, Macomics. He is currently a Principal Investigator at the University of Edinburgh.
30 years’ industry experience
ex-VP of Immuno-oncology at F-star working on bispecific antibody therapies targeting T cells
Headed the Immunology department at ImClone taking antibody programs to clinical stage, including macrophage program on CSF-1R
Heads Tumor Microenvironment Lab working on TAMs, tumour angiogenesis and immunotherapies
His previous work has led to the first-in-kind clinical trials of engineered monocytes in patients with brain and haematological cancers